Skip to content

Released Nov 6, 2024, after the close

10-Q filed Nov 7, 2024, 38 days after period end · 0001636422-24-000152

Q3 2024 · 10-Q
Revenue$76.35M+3.5% vs Q3 2023+0.6% vs Q2 2024
Net Income-$14.73MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.24N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$36,289,000—
Operating Income-$13,687,000N/M
Operating Cash Flowderived$6,208,000+99.3%
Free Cash Flowderived$5,503,000+85.5%
Margins · derived
Gross margin47.5%
Operating margin-17.9%+15.4 pt vs Q3 2023
Net margin-19.3%+10.6 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$76.35M$73.77M$68.35M$61.74M
Net Income-$14.73M-$22.03M-$45.74M-$40.01M
EPS Diluted-$0.24-$0.39-$0.84-$0.82

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR